Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q1 2026 · 10-Q
Revenue$100.00K$100.00K— vs Q1 2025 Net Income-$5.72M-$5.72MN/M vs Q1 2025 EPS Diluted-$0.11-$0.11N/M vs Q1 2025 Operating Income-$5,951,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Free Cash Flowderived-$5,697,000N/M Margins · derivedOperating margin-5951.0%
Net margin-5720.0%
ended Sep 30, 2025 · filed Nov 12, 2025 · 43 d after period end